Investors have filed a securities class action against Replimune Group, alleging the company misled shareholders about its RP1 drug trial design and FDA regulatory strategy. The lawsuit claims Replimune used single-arm trial designs and response criteria previously questioned by the FDA, failing to disclose these issues while presenting the resubmission as complete. Following these revelations, Replimune's stock price dropped sharply, losing over 84% from its high in December 2025 to April 2026. Investors who bought shares between October 2025 and April 2026 may seek recovery, with motions for lead plaintiff due by October 5, 2026.
Replimune Group shares are the subject of a securities class action lawsuit. For readers following the health sector, here is Pluang's market snapshot as of Sep 30, 2026 23:01 WIB: 54 of 100 priced health-sector US stocks rose today, while 46 fell. Notable movers include RXRX at USD 4.19 with a 3.97% increase and 100% buy order activity, AMWL at USD 13.63 with a 3.73% rise and 100% sell order activity, and TXG at USD 93.35 with a 3.68% gain and mixed buy/sell activity.
Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Anavex Life Sciences securities between November 26, 2025, and August 28, 2026. The lawsuit alleges that Anavex made false or misleading statements and failed to dis...
Hyperliquid (HYPE) saw its price increase by 5.80% within four hours to reach $89.76 on September 30, extending its 24-hour gain to 3.86%. The price moved up from $84.84 earlier in the day, with trading data sourced from Binance spot HYPE/USDT prices...
In 2026, international stocks have gained significant momentum, making Vanguard's Total International Stock Index Fund Admiral Shares (VTIAX) an attractive option for U.S. investors seeking global exposure. The fund tracks a broad index covering deve...
Masco Corporation has been upgraded to a buy rating due to its resilience in a tough macroeconomic and housing market environment. The company's 89% exposure to repair and remodel work helps shield it from volatility in new construction, supporting s...
Bitcoin has surged about 42.5% in Q3, marking its second-strongest third quarter since 2013, but Bitfinex analysts warn that further sustained gains depend on increased spot market buying. Reduced leverage and slower ETF inflows have lessened liquida...
